The partnership aims to advance pharmaceutical and life sciences ventures originating from BIRAD- Bar-Ilan University, turning laboratory discoveries into solutions that address unmet medical needs.

(RTTNews) - Hadasit Medical Research Services and Development and BIRAD - Research & Development Company Ltd. have entered into the research and license agreement with Immix BioPharma for the ...

Cost-effectiveness of letrozole and anastrozole as adjuvant therapy for hormone receptor positive early breast cancer in postmenopausal women No significant financial relationships to disclose. This ...

The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy at ...

Agreement signed following positive pre-clinical data demonstrating a one-time treatment with PLX-PAD significantly increased neurogenesis, offering immediate, long-term therapeutic effect in treating ...

Accuracy and upgrade rates of stereotactic vacuum-assisted breast biopsy: Impact of number of core samples taken on malignancy underestimation rates. Background: The shift from the use of BrMR for ...